Here are 1-3 brief analogies for Centene (CNC):

• Think of it as Humana, but specialized in Medicaid and Medicare-Medicaid plans.
• The UnitedHealth Group for government-sponsored health programs.

• Government-Sponsored Health Plans: Centene offers comprehensive health plan coverage to individuals enrolled in government-subsidized programs such as Medicaid, the State Children's Health Insurance Program (CHIP), and Medicare-Medicaid plans.
• Commercial Healthcare Products: The company provides various health insurance products for individuals, small groups, and large commercial groups, directly to members and employers.
• Pharmacy Benefits Management (PBM) Services: Centene delivers services focused on managing prescription drug benefits for various clients, including state programs and healthcare organizations.
• Specialty Healthcare Services: This category includes nurse advice lines, after-hours support, vision and dental services, and specialized offerings for Military Health System beneficiaries.
• Staffing Services: Centene provides staffing solutions to correctional systems and other government agencies.

Major Customers of Centene (CNC)

Centene primarily serves individuals, with a significant portion of its business derived from managing government-subsidized healthcare programs for these individuals. Additionally, it sells commercial health plans directly to individuals and employer groups, and provides specialty services to government agencies and commercial organizations. Its major customer categories are:

• Individuals covered by Government-Sponsored Programs: This category includes individuals enrolled in Medicaid, the State Children's Health Insurance Program (SCHIP), Medicare-Medicaid plans, long-term services and support, foster care programs, and aged, blind, or disabled programs. Centene contracts with state and federal governments to provide comprehensive healthcare services to these beneficiaries.
• Individuals and Employer Groups Purchasing Commercial Health Plans: Centene offers various individual, small group, and large group commercial healthcare products. This includes individuals who directly purchase health plans, as well as employers who provide Centene's health products as part of their employee benefits.
• Government Agencies and Correctional Facilities: Centene's Specialty Services segment provides services such as pharmacy benefits management, nurse advice lines, vision and dental services, and staffing services directly to state programs, correctional systems, the Military Health System, and other government agencies.

Sarah M. London, Chief Executive Officer

Sarah London was appointed CEO of Centene Corporation in March 2022, becoming the youngest female CEO of a Fortune 500 company at the time. Prior to her CEO appointment, she served as Centene's Vice Chairman, where she was responsible for strategy, technology, ancillary services, enterprise compliance and quality, and Centene's portfolio of independent, non-health plan companies. Before joining Centene in 2020, she was an Operating Partner at Optum Ventures, the venture capital arm of UnitedHealth Group. Her career also includes leadership roles at Optum Analytics, where she was Chief Product Officer, and at Humedica, a clinical analytics start-up acquired by Optum. She also held positions at Accretive Health (now R1 RCM) and Health Leads.

Drew Asher, Executive Vice President and Chief Financial Officer

Drew Asher was appointed Executive Vice President and Chief Financial Officer of Centene Corporation in May 2021. He joined Centene in January 2020 following the acquisition of WellCare Health Plans, where he had served as Chief Financial Officer for six years, starting in 2014. Before his tenure at WellCare, Mr. Asher held senior finance positions, including Chief Financial Officer of Aetna's local and regional businesses, a role he assumed after Coventry Health Care was acquired by Aetna in May 2013. He spent 15 years at Coventry Health Care, most recently as Senior Vice President, Corporate Finance. He began his career as an auditor and accountant at Deloitte & Touche LLP.

Ken Fasola, President

Ken Fasola was named President of Centene Corporation in December 2022. Prior to this role, he served as Centene's Executive Vice President of Health Care Enterprises and was a member of the Office of the CEO. Mr. Fasola joined Centene through the acquisition of Magellan Health Inc., where he was the Chief Executive Officer and a member of the Board of Directors. He also served as Chairman, President, and CEO of HealthMarkets, Inc., a company later acquired by UnitedHealth Group in 2019. His extensive healthcare career spans over three decades, including nearly twenty years in executive leadership roles at UnitedHealth Group and Humana, where he was CEO of Secure Horizons (a division of UnitedHealth Group) and COO of Market Operations, respectively.

Jim Murray, Executive Vice President, Chief Operating Officer

Jim Murray was appointed Executive Vice President, Chief Operating Officer of Centene Corporation in December 2022. Previously, he served as Centene's Chief Transformation Officer, where he led the company's Value Creation Office and the Centene Advanced Behavioral Health division. Before joining Centene, Mr. Murray was President and Chief Operating Officer for Magellan Health, which Centene acquired in January 2022. His experience also includes serving as President of PrimeWest Health and Chief Executive Officer of LifeCare HealthPartners, a hospital system. Earlier in his career, he held the position of Executive Vice President and Chief Operating Officer for Humana.

Brent Layton, Senior Advisor to the CEO

As of December 2022, Brent Layton transitioned to the role of Senior Advisor to the CEO at Centene Corporation, beginning his move towards retirement. He previously served as Centene's President and Chief Operating Officer, a role he held after being appointed President of U.S. Health Plans, Products, and International in March 2021, and subsequently COO in September 2021. Mr. Layton joined Centene in 2006, following five years as a consultant for the company. With over 30 years of experience in the healthcare and public policy sectors, he previously operated a managed care consulting firm and founded and managed various healthcare companies, including Avesis and Absolute Care Medical Centers.

The key risks to Centene Corporation's (CNC) business are primarily rooted in its significant reliance on government-sponsored healthcare programs and the dynamic regulatory and cost environment of the healthcare sector.

1. Regulatory Risks and Government Policy Changes: Centene derives a substantial portion of its revenue from government-backed healthcare programs, including Medicaid, the Affordable Care Act (ACA) marketplace, and Medicare. Consequently, the company is highly susceptible to shifts in government policies, funding, and regulations. These changes can include reductions in Medicaid funding, the expiration of ACA subsidies, and unfavorable adjustments in risk adjustment mechanisms, all of which can directly impact membership numbers, reimbursement rates, and overall profitability. For instance, recent reports indicated Centene's shares plummeted amid concerns over ACA membership declines, and there have been proposals to redirect federal healthcare funds directly to individuals, bypassing traditional insurers.

2. Rising Healthcare Costs and Medical Utilization: Centene faces significant pressure from escalating healthcare costs, particularly in areas such as behavioral health, home health services, and high-cost prescription drugs. These rising costs, especially within Medicaid programs and ACA marketplace operations, can erode the company's margins if reimbursement rates from government contracts do not adequately keep pace. This mismatch between increasing medical costs and static or insufficient reimbursement rates poses a continuous challenge to Centene's profitability.

3. Legal and Regulatory Scrutiny of PBM Practices: Centene has a history of facing legal and regulatory challenges related to its pharmacy benefit management (PBM) business model. The company has been subject to investigations and multi-state settlements over allegations of overpayments by state Medicaid programs. Furthermore, a class-action lawsuit has been filed, alleging securities fraud and corporate misrepresentation concerning Centene's compliance with state Medicaid billing practices and its PBM operations. These legal headwinds can result in substantial financial penalties, increased legal expenses, and reputational damage.

New technology-first healthcare enterprises leveraging advanced artificial intelligence and data analytics to provide highly efficient, personalized, and proactive managed care services for government-subsidized populations. These emerging entities could challenge Centene's ability to win and retain state contracts by demonstrating superior outcomes, lower administrative costs, and enhanced member experiences through their innovative use of technology, potentially disintermediating Centene's traditional, network-heavy model.

Centene Corporation (CNC) operates in several large addressable markets within the U.S. healthcare sector, primarily focusing on government-sponsored programs and specialty services.

Managed Care

• Medicaid: The total Managed Medicaid market, covering both managed care and fee-for-service, reached 70.5 million people in June 2025. In FY 2023, state and federal spending on Medicaid services totaled over $880 billion, with payments to comprehensive risk-based Managed Care Organizations (MCOs) accounting for about 52% of this total. As of March 2025, Centene led the national Medicaid managed care market with 17.7% market share, out of an estimated 66 million enrollees in Medicaid managed care programs across 41 states. Centene directly served 12 million Managed Medicaid members at the end of Q2 2025.
• Medicare Advantage: The Medicare Advantage market in the U.S. saw 32.8 million people enrolled in 2024, representing 54% of the eligible Medicare population. This market grew to 34.5 million members in 2024. The Medicare Advantage market size within the U.S. reached 34.1 million beneficiaries in 2025. The global Medicare Advantage market, largely driven by the U.S., was estimated at USD 445.97 billion in 2025 and is projected to grow to USD 1,060.04 billion by 2034.

Specialty Services

• Pharmacy Benefits Management (PBM): The U.S. pharmacy benefit management market size was estimated at USD 519.45 billion in 2025. Another estimate puts the U.S. PBM market size at USD 459.65 billion in 2025, projected to reach approximately USD 1,041.11 billion by 2034. The U.S. market stood at USD 626.47 billion in 2026.
• Dental Services: The U.S. dental services market size was estimated at USD 174.91 billion in 2025 and is predicted to increase to approximately USD 281.20 billion by 2035. Another report valued the U.S. dental services market at USD 174.2 billion in 2025, growing to an estimated USD 234.11 billion by 2031.
• Vision Care: The U.S. eye care market size was estimated at USD 27.3 billion in 2024 and is expected to reach USD 29.00 billion in 2025. The demand for vision care in the USA is projected to grow from USD 37.2 billion in 2025 to USD 71.5 billion by 2035. The overall U.S. optical industry achieved a total market value of $68.3 billion in 2024.

Centene Corporation (CNC) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily stemming from its government-sponsored healthcare programs, despite some headwinds in other segments.

1. Growth in Medicare Business, particularly Prescription Drug Plans (PDP): Centene expects its Medicare segment to be a significant driver of revenue growth. Management projects an increase in Medicare premium revenue of approximately $7.5 billion in 2026, largely fueled by its Prescription Drug Plan (PDP) business, which is tracking for high single-digit percentage growth in Part D enrollment.
2. Favorable Medicaid Rate Adjustments: While Centene expects a decline in Medicaid member months, the company is implementing mid-4% net rate increases for 2026. These favorable rate adjustments contribute positively to the premium revenue generated within its Medicaid programs, helping to offset the impact of membership attrition.
3. Strategic Pricing in the Health Insurance Marketplace: Although the Health Insurance Marketplace segment is projected to experience a decrease in overall revenue, Centene has undertaken strategic pricing actions and product mix adjustments for 2026. These initiatives are aimed at improving pretax margins and stabilizing revenue yield from its member base in this segment.

Share Repurchases

• Centene repurchased 42.0 million shares for $3.0 billion in 2024 through its stock repurchase program.
• The company's annual share buybacks were $475 million in 2025 and $1.633 billion in 2023.
• As of December 31, 2024, Centene was authorized to repurchase up to $10.0 billion of its stock, with $2.2 billion remaining under this authorization.

Share Issuance

• Centene's shares outstanding declined to 0.493 billion in 2025, a 5.85% decrease from 2024.
• Shares outstanding further decreased by 4.02% in 2024 to 0.524 billion, and by 6.24% in 2023 to 0.546 billion, indicating net share repurchases over new issuances.
• As of July 23, 2025, Centene had 491.133 million shares of common stock outstanding.

Outbound Investments

• Centene acquired Magellan Health for $2.2 billion in January 2021.
• Centene acquired the remaining equity interests in Circle Health in July 2021 and subsequently signed an agreement to sell Circle Health Group for approximately $1.2 billion (inclusive of debt assumed) in August 2023.
• In December 2024, Centene executives indicated a focus on acquiring health plans or other assets in 2025 to boost efforts in ICHRA and dual-eligible markets.

Capital Expenditures

• Centene's long-term investments for 2024 were $17.429 billion, marking a 7.02% increase from 2023.
• Long-term investments grew to $16.286 billion in 2023, an increase of 10.91% from 2022.
• The company reported $18.180 billion in long-term investments for the quarter ending December 31, 2025.